medigraphic.com
ISSN 2500-7106 (Digital)
ISSN 0123-2576 (Impreso)
Medicina & Laboratorio

2011, Número 03-04

<< Anterior Siguiente >>

Medicina & Laboratorio 2011; 17 (03-04)


Péptido natriurético cerebral: utilidad clínica

Saldarriaga GC, Jiménez GCA, Ramírez BJD, Cardona GMC

Idioma: Español
Referencias bibliográficas: 57
Paginas: 127-144
Archivo PDF: 949.65 Kb.


RESUMEN

El descubrimiento de biomarcadores específicos de una enfermedad brinda la única oportunidad de adelantarse al diagnóstico clínico de la entidad. Esto aporta ventajas en el tratamiento de los pacientes que se verán reflejadas en los desenlaces. Hoy día se dispone del péptido natriurético cerebral como un biomarcador ampliamente estudiado y con validación clínica, no sólo en la falla cardiaca, sino en otras condiciones comórbidas importantes. La presente revisión pretende dar una visión general del origen, del mecanismo de acción y de la utilidad clínica del péptido en las principales enfermedades cardiovasculares.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Ronco C, House AA, Haapio M. Cardiorenal syndrome: refining the definition of a complex symbiosis gone wrong. Intensive Care Med 2008; 34: 957-962.

  2. Braunwald E. Biomarkers in heart failure. N Engl J Med 2008; 358: 2148-2159.

  3. Braunwald E, Harrison DC, Chidsey CA. The Heart as an Endocrine Organ. Am J Med 1964; 36: 1-4.

  4. De Bold AJ. Heart atria granularity effects of changes in water-electrolyte balance. Proc Soc Exp Biol Med 1979; 161: 508-511.

  5. De Bold AJ, Bencosme SA. Studies on the relationship between the catecholamine distribution in the atrium and the specific granules present in atrial muscle cells. 2. Studies on the sedimentation pattern of atrial noradrenaline and adrenaline. Cardiovasc Res 1973; 7: 364-369.

  6. De Bold AJ, Bencosme SA. Studies on the relationship between the catecholamine distribution in the atrium and the specific granules present in atrial muscle cells. 1. Isolation of a purified specific granule subfraction. Cardiovasc Res 1973; 7: 351-363.

  7. Dzau VJ, Brenner A, Emmett N, Haber E. Identification of renin and renin-like enzymes in rat brain by a renin-specific antibody. Clin Sci (Lond) 1980; 59 Suppl 6: 45s-47s.

  8. Baliga RR, Young JB. Editorial: Do biomarkers deserve high marks? Heart Fail Clin 2009; 5: ix-xii.

  9. Gupta S, Drazner MH, de Lemos JA. Newer biomarkers in heart failure. Heart Fail Clin 2009; 5: 579-588.

  10. de Bold AJ, Borenstein HB, Veress AT, Sonnenberg H. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci 1981; 28: 89-94.

  11. Burnett JC, Jr. Vasopeptidase inhibition: a new concept in blood pressure management. J Hypertens Suppl 1999; 17: S37-43.

  12. Potter LR, Abbey-Hosch S, Dickey DM. Natriuretic peptides, their receptors, and cyclic guanosine monophosphate- dependent signaling functions. Endocr Rev 2006; 27: 47-72.

  13. Munagala VK, Burnett JC, Jr., Redfield MM. The natriuretic peptides in cardiovascular medicine. Curr Probl Cardiol 2004; 29: 707-769.

  14. Ruskoaho H. Cardiac hormones as diagnostic tools in heart failure. Endocr Rev 2003; 24: 341-356.

  15. Azzazy HM, Christenson RH. B-type natriuretic peptide: physiologic role and assay characteristics. Heart Fail Rev 2003; 8: 315-320.

  16. Cody RJ, Atlas SA, Laragh JH, Kubo SH, Covit AB, Ryman KS, et al. Atrial natriuretic factor in normal subjects and heart failure patients. Plasma levels and renal, hormonal, and hemodynamic responses to peptide infusion. J Clin Invest 1986; 78: 1362-1374.

  17. Mukoyama M, Nakao K, Hosoda K, Suga S, Saito Y, Ogawa Y, et al. Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest 1991; 87: 1402-1412.

  18. Omland T, Hagve TA. Natriuretic peptides: physiologic and analytic considerations. Heart Fail Clin 2009; 5: 471-487.

  19. Sharp A, Mayet J. The utility of BNP in clinical practice. J Renin Angiotensin Aldosterone Syst 2004; 5: 53-58.

  20. Clerico A, Iervasi G, Mariani G. Pathophysiologic relevance of measuring the plasma levels of cardiac natriuretic peptide hormones in humans. Horm Metab Res 1999; 31: 487-498.

  21. Liu P, Arnold JM, Belenkie I, Demers C, Dorian P, Gianetti N, et al. The 2002/3 Canadian Cardiovascular Society consensus guideline update for the diagnosis and management of heart failure. Can J Cardiol 2003; 19: 347-356.

  22. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005; 112: e154-235.

  23. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008; 29: 2388-2442.

  24. Omland T. Advances in congestive heart failure management in the intensive care unit: B-type natriuretic peptides in evaluation of acute heart failure. Crit Care Med 2008; 36: S17-27.

  25. Moe GW. B-type natriuretic peptide in heart failure. Curr Opin Cardiol 2006; 21: 208-214.

  26. Apple FS, Wu AH, Jaffe AS, Panteghini M, Christenson RH, Cannon CP, et al. National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine practice guidelines: Analytical issues for biomarkers of heart failure. Circulation 2007; 116: e95-98.

  27. McCullough PA, Duc P, Omland T, McCord J, Nowak RM, Hollander JE, et al. B-type natriuretic peptide and renal function in the diagnosis of heart failure: an analysis from the Breathing Not Properly Multinational Study. Am J Kidney Dis 2003; 41: 571-579.

  28. Burke MA, Cotts WG. Interpretation of B-type natriuretic peptide in cardiac disease and other comorbid conditions. Heart Fail Rev 2007; 12: 23-36.

  29. Tosa S, Watanabe H, Iino K, Terui G, Kosaka T, Hasegawa H, et al. Usefulness of plasma BNP levels as a marker of left ventricular wall stress in obese individuals. Int Heart J 2009; 50: 173-182.

  30. Iwanaga Y, Kihara Y, Niizuma S, Noguchi T, Nonogi H, Kita T, et al. BNP in overweight and obese patients with heart failure: an analysis based on the BNP-LV diastolic wall stress relationship. J Card Fail 2007; 13: 663-667.

  31. Raymond I, Groenning BA, Hildebrandt PR, Nilsson JC, Baumann M, Trawinski J, et al. The influence of age, sex and other variables on the plasma level of Nterminal pro brain natriuretic peptide in a large sample of the general population. Heart 2003; 89: 745-751.

  32. Das SR, Drazner MH, Dries DL, Vega GL, Stanek HG, Abdullah SM, et al. Impact of body mass and body composition on circulating levels of natriuretic peptides: results from the Dallas Heart Study. Circulation 2005; 112: 2163-2168.

  33. Anwaruddin S, Lloyd-Jones DM, Baggish A, Chen A, Krauser D, Tung R, et al. Renal function, congestive heart failure, and amino-terminal pro-brain natriuretic peptide measurement: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Study. J Am Coll Cardiol 2006; 47: 91-97.

  34. Tang WH. Natriuretic peptides in screening for cardiac dysfunction. Heart Fail Clin 2006; 2: 323-332.

  35. Prontera C, Zaninotto M, Giovannini S, Zucchelli GC, Pilo A, Sciacovelli L, et al. Proficiency testing project for brain natriuretic peptide (BNP) and the N-terminal part of the propeptide of BNP (NT-proBNP) immunoassays: the CardioOrmocheck study. Clin Chem Lab Med 2009; 47: 762-768.

  36. Maisel A. B-type natriuretic peptide levels: diagnostic and prognostic in congestive heart failure: what’s next? Circulation 2002; 105: 2328-2331.

  37. Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Duc P, et al. Rapid measurement of Btype natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002; 347: 161-167.

  38. Januzzi JL, Jr., Camargo CA, Anwaruddin S, Baggish AL, Chen AA, Krauser DG, et al. The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol 2005; 95: 948-954.

  39. Hoyne J. Heart failure and B-type natriuretic protein. Clin Lab Sci 2009; 22: 233-239.

  40. Porapakkham P, Porapakkham P, Zimmet H, Billah B, Krum H. B-type natriuretic peptide-guided heart failure therapy: A meta-analysis. Arch Intern Med; 2010; 170: 507-514.

  41. Maisel AS, Koon J, Krishnaswamy P, Kazenegra R, Clopton P, Gardetto N, et al. Utility of B-natriuretic peptide as a rapid, point-of-care test for screening patients undergoing echocardiography to determine left ventricular dysfunction. Am Heart J 2001; 141: 367-374.

  42. Krishnaswamy P, Lubien E, Clopton P, Koon J, Kazanegra R, Wanner E, et al. Utility of B-natriuretic peptide levels in identifying patients with left ventricular systolic or diastolic dysfunction. Am J Med 2001; 111: 274-279.

  43. Lubien E, DeMaria A, Krishnaswamy P, Clopton P, Koon J, Kazanegra R, et al. Utility of B-natriuretic peptide in detecting diastolic dysfunction: comparison with Doppler velocity recordings. Circulation 2002; 105: 595-601.

  44. Heart Failure Society Of A. Evaluation of patients for ventricular dysfunction and heart failure. J Card Fail 2006; 12: e16-25.

  45. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009; 119: e391-479.

  46. de Lemos JA, Morrow DA, Bentley JH, Omland T, Sabatine MS, McCabe CH, et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 2001; 345: 1014-1021.

  47. Morrow DA, de Lemos JA, Blazing MA, Sabatine MS, Murphy SA, Jarolim P, et al. Prognostic value of serial B-type natriuretic peptide testing during follow-up of patients with unstable coronary artery disease. Jama 2005; 294: 2866-2871.

  48. Schnabel R, Lubos E, Rupprecht HJ, Espinola-Klein C, Bickel C, Lackner KJ, et al. B-type natriuretic peptide and the risk of cardiovascular events and death in patients with stable angina: results from the AtheroGene study. J Am Coll Cardiol 2006; 47: 552-558.

  49. Mollmann H, Nef HM, Kostin S, Dragu A, Maack C, Weber M, et al. Ischemia triggers BNP expression in the human myocardium independent from mechanical stress. Int J Cardiol 2010; 143: 289-297.

  50. Yusoff R, Clayton N, Keevil B, Morris J, Ray S. Utility of plasma N-terminal brain natriuretic peptide as a marker of functional capacity in patients with chronic severe mitral regurgitation. Am J Cardiol 2006; 97: 1498-1501.

  51. Talha S, Di Marco P, Doutreleau S, Rouyer O, Piquard F, Geny B. Does circulating BNP normalize after heart transplantation in patients with normal hemodynamic and right and left heart functions? Clin Transplant 2008; 22: 542-548.

  52. Talha S, Charloux A, Enache I, Piquard F, Geny B. Mechanisms involved in increased plasma brain natriuretic peptide after heart transplantation. Cardiovasc Res 2010; doi:10.1093/cvr/cvq331.

  53. Hervas I, Arnau MA, Almenar L, Perez-Pastor JL, Chirivella M, Osca J, et al. Ventricular natriuretic peptide (BNP) in heart transplantation: BNP correlation with endomyocardial biopsy, laboratory and hemodynamic measures. Lab Invest 2004; 84: 138-145.

  54. Park MH, Uber PA, Scott RL, Mehra MR. B-type natriuretic peptide in heart transplantation: an important marker of allograft performance. Heart Fail Rev 2003; 8: 359-363.

  55. Torbicki A, Perrier A, Konstantinides S, Agnelli G, Galie N, Pruszczyk P, et al. Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Eur Heart J 2008; 29: 2276-2315.

  56. Galie N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009; 30: 2493-2537.

  57. Tang WH, Francis GS, Morrow DA, Newby LK, Cannon CP, Jesse RL, et al. National Academy of Clinical Biochemistry Laboratory Medicine practice guidelines: Clinical utilization of cardiac biomarker testing in heart failure. Circulation 2007; 116: e99-109.




2020     |     www.medigraphic.com